Abciximab does not prevent ischemic lesions related to cerebral angiography: a randomized placebo-controlled trial

Cerebrovasc Dis. 2011;31(4):353-7. doi: 10.1159/000323219. Epub 2011 Jan 7.

Abstract

Background: To assess the efficiency of IIb/IIIa platelet receptor inhibition by abciximab in the prevention of silent embolism during digital subtraction angiography.

Methods: In this randomized, double-blind, prospective study, pre- and postangiographic diffusion-weighted magnetic resonance imaging (DWI) of 184 participants was evaluated for the occurrence of silent embolism.

Results: No significant relationship was found between the patients receiving abciximab before digital subtraction angiography (15 of 90; 16.7%) and patients in the placebo group (16 of 94; 17.0%) regarding postangiographic appearance of silent emboli (p = 0.9).

Conclusions: IIb/IIIa receptor inhibition by abciximab does not diminish the occurrence of silent embolism during digital subtraction angiography. Our findings indicate that solid blood clots are not the origin of hyperintense lesions observed on DWI and enhance the role of alternative mechanisms.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Abciximab
  • Angiography, Digital Subtraction / adverse effects*
  • Antibodies, Monoclonal / therapeutic use*
  • Brain Ischemia / blood
  • Brain Ischemia / diagnosis
  • Brain Ischemia / etiology
  • Brain Ischemia / prevention & control*
  • Cerebral Angiography / adverse effects*
  • Diffusion Magnetic Resonance Imaging
  • Double-Blind Method
  • Female
  • Germany
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use*
  • Intracranial Embolism / blood
  • Intracranial Embolism / diagnosis
  • Intracranial Embolism / etiology
  • Intracranial Embolism / prevention & control*
  • Male
  • Middle Aged
  • Placebo Effect
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
  • Prospective Studies
  • Risk Factors
  • Treatment Failure

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Abciximab